Company intelligence
Decoy Therapeutics Inc.
Pioneering D-MAVs, Designable Multi-Antivirals engineered to target what viruses share.
About Decoy Therapeutics Inc.
At Decoy, we are pioneering a new category of antiviral medicine. Designable Multi-Antivirals (D-MAVs) are engineered to target shared viral mechanisms, enabling a single, adaptable drug to work across multiple viruses. Not one drug for one virus. One platform for many. Built on our proprietary IMP³ACT platform, which integrates rapid peptide synthesis with AI-enabled design, D-MAVs are designed to move faster into the clinic, learn across programs, and reach the people who need them. Viral disease doesn't just make you sick. It disrupts everything around you. We're building with that reality in mind. [decoytx.com]
Verified activity
Signals from Decoy Therapeutics Inc.
3 published signals
Presence & Recognition
Decoy Therapeutics Inc. will present at the Moody Capital Solutions, Inc. 2026 Disruptive Growth & Life Sciences Conference in New York.
Reported by Decoy Therapeutics Inc.
Products & Services
Decoy Therapeutics Inc. launched a new brand, new website, and new look and feel.
Reported by Decoy Therapeutics Inc.
Products & Services
Decoy Therapeutics Inc. created a new category of antiviral medicine called Designable Multi-Antivirals or D-MAVs.
Reported by Decoy Therapeutics Inc.